The omega 3 prescription drugs market is projected to grow from USD 1.6 billion in 2025 to USD 3.6 billion by 2035, at a CAGR of 8.2%. Vascepa will dominate with a 54.0% market share, while cardiovascular diseases will lead the application segment with a 62.0% share.